4 citations
,
September 2006 in “European Journal of Clinical Pharmacology” This study concluded that finasteride 1 mg does not significantly affect the metabolism of omeprazole in young healthy Japanese male extensive or poor metabolizers for CYP2C19.
November 2020 in “Journal of Pharmaceutical Sciences” This study suggests a decision tree using in vitro metabolic clearance to identify early drug candidates likely to experience nonlinear pharmacokinetics due to intestinal CYP3A-related metabolism.
October 2024 in “Frontiers in Pharmacology” This study found that in patients with genetic generalized epilepsies, certain gene variants were linked to differences in valproic acid treatment outcomes, including a higher likelihood of treatment failure, varying serum drug concentrations, and specific side effects like weight gain and hair loss.
5 citations
,
January 2017 in “Nevrologiâ, nejropsihiatriâ, psihosomatika” In this study, sustained-release sodium valproate showed high efficacy in achieving seizure remission for adults with focal and generalized epilepsy over one year, but side effects like weight gain and tremor were more frequent among heterozygous carriers of certain gene variants.
June 2023 in “International Journal of Pharmaceuticals Nutraceuticals and Cosmetic Science” This review compiles recent findings on the pharmacokinetics, pharmacodynamics, and pharmacogenomics of Valproate, highlighting potential new uses, benefits, and risks, but reports no new clinical results.